Characterization of Dosage of Attention-Deficit/Hyperactivity Disorder (ADHD) Stimulant Medications: A Descriptive Analysis

In the first four reports included in this analysis, we examined dosage of stimulant medications approved for treatment of attention-deficit/hyperactivity disorder (ADHD) within pre- and post-COVID-19 pandemic time periods in the Sentinel Distributed Database (SDD). The overall study period includes data from January 1, 2017 to March 31, 2023. We distributed this request to eight Sentinel Data Partners on May 23, 2024. 

The first four reports are as follows:

• Report 1: This report examines dosage during the overall study period: January 1, 2017 to March 31, 2023.
• Report 2: This report examines dosage during the pre-pandemic period: April 1, 2018 to March 31, 2020.
• Report 3: This report examines dosage during the pandemic period: April 1, 2020 to March 31, 2022.
• Report 4: This report examines dosage during the post-pandemic period: April 1, 2022 to March 31, 2023.

In an additional report included with this analysis (Report 5), we compared characteristics among individuals who initiated stimulant and non-stimulant medications approved for the treatment of ADHD in the SDD, between the pre-pandemic (April 1, 2018, to March 31, 2020) and pandemic (April 1, 2020 to March 31, 2022) time periods. The Report 5 study period includes data from April 1, 2018 to March 31, 2022. We distributed this request to eight Sentinel Data Partners on June 14, 2024.